KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Receivables: 2010-2025

Historic Receivables for Neogenomics (NEO) over the last 15 years, with Sep 2025 value amounting to $155.3 million.

  • Neogenomics' Receivables rose 2.55% to $155.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $610.3 million, marking a year-over-year increase of 7.10%. This contributed to the annual value of $150.6 million for FY2024, which is 14.76% up from last year.
  • As of Q3 2025, Neogenomics' Receivables stood at $155.3 million, which was up 1.42% from $153.1 million recorded in Q2 2025.
  • Neogenomics' Receivables' 5-year high stood at $155.3 million during Q3 2025, with a 5-year trough of $105.3 million in Q1 2021.
  • Over the past 3 years, Neogenomics' median Receivables value was $146.6 million (recorded in 2024), while the average stood at $141.8 million.
  • Data for Neogenomics' Receivables shows a peak YoY grew of 21.52% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Neogenomics' Receivables stood at $114.1 million in 2021, then rose by 6.60% to $121.6 million in 2022, then grew by 7.91% to $131.3 million in 2023, then rose by 14.76% to $150.6 million in 2024, then increased by 2.55% to $155.3 million in 2025.
  • Its last three reported values are $155.3 million in Q3 2025, $153.1 million for Q2 2025, and $151.2 million during Q1 2025.